DraftKings, H&R Block, Novartis and More Wednesday Afternoon Analyst Calls24/7 Wall Street • 03/10/21
Why 2 Acadia Pharma Analysts Are Bracing For FDA Rejection Of Nuplazid In DementiaBenzinga • 03/09/21
Acadia plummets 49% after FDA decision dims chances of label expansion for key drug (ACAD)Business Insider • 03/09/21
SHAREHOLDER ALERT: Acadia Pharmaceuticals Inc. Investigated for Possible Securities Laws Violations by Block & Leviton LLP; Investors Should Contact the FirmNewsfile Corp • 03/09/21
Acadia Pharmaceuticals stock leads premarket losers after FDA finds undisclosed 'deficiencies' in NDAMarket Watch • 03/09/21
Acadia Pharmaceuticals Crashes On FDA Setback For Psychosis TreatmentInvestors Business Daily • 03/08/21
Acadia Pharmaceuticals Provides Regulatory Update on Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related PsychosisBusiness Wire • 03/08/21
ACADIA Pharmaceuticals, Inc. (ACAD) Presents at Cowen Healthcare Broker Conference Call - (Transcript)Seeking Alpha • 03/02/21
ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/25/21
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial ResultsBusiness Wire • 02/24/21
Acadia Pharmaceuticals Recognizes National Caregiver's Day with Launch of MoreThanMemoryLoss.comBusiness Wire • 02/19/21
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021Business Wire • 02/10/21
ACADIA Pharmaceuticals Inc.'s (ACAD) CEO Stephen Davis at 39th Annual J.P. Morgan Healthcare Conference (Transcript)Seeking Alpha • 01/12/21
Acadia Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021Business Wire • 12/22/20